ClinicalTrials.gg
CompletedNCT04944966MALHERBALUpdated Jul 18, 2023

Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria

A Phase 2 interventional study of Maytenus Senegalensis in Malaria, sponsored by Ifakara Health Institute. Completed at 1 site in Tanzania. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-18.

Sponsored by Ifakara Health Institute · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Malaria with a site in Tanzania — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Tanzania.

Enrollment
69th of 72
12 · median 616
Started
2021
with 2 others
Phase 2
6 of 79
none open now
Registered
70th of 79
by date
Lead sponsor
6 of 79
Ifakara Health Institute

Among the 79 studies in Malaria with a site in Tanzania, this one is the 69th largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2021, is one of 6 in phase 2, and was the 70th registered.

Malaria

1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 79 studies in Malaria with a site in Tanzania are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Tanzania have not opened yet or have stopped. Only those recruiting at a site in Tanzania →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Malaria with a site in Tanzania, or all of them as a file.
02

Study summary

Antimalarial Herbal medicine known as Maytenus senegalensis will be evaluated for its safety, tolerability and efficacy among Tanzanian male adults aged 18 to 45 years. The first primary objective is to assess the safety and tolerability of malaria herbal remedy of Maytenus senegalensis among healthy male adults aged 18 to 45 years in Tanzania. And the second objective is to evaluate the safety, tolerability as well as efficacy of malaria herbal remedy Maytenus senegalensis (MALHERBAL) for the treatment of Tanzanian adults aged 18 to 45 years with uncomplicated malaria compared to Artemether-lumefantrine.

Read the detailed description

The herbal medicine (Maytenus senegalensis) has been scientifically investigated for acute toxicity in vitro and antiplasmodial activity both in vitro and in vivo where it showed strong antimalarial activity. However, to our knowledge, no antimalarial studies have been performed on this herbal medicine in standardized clinical settings.

The study will contain two treatment groups. Group 1 will have 12 healthy male adults aged 18 to 45 years who will be given the malaria herbal remedy (Maytenus senegalensis) and followed up for safety for 56 days. The subgroup 1a will be the first group to be enrolled in the study and given Malaria herbal remedy. The safety assessment of this group will be done in 7 days after the first treatment. If there will be no major safety concern per-protocol among participants of group 1a, the subgroup 1b participants will be enrolled in the study and given Malaria herbal remedy. The safety assessment of this subgroup 1b will be done 7 days after the first treatment. If there will be no major safety concern per-protocol among participants of group 1b, the subgroup 1c participants will be enrolled in the study and given Malaria herbal remedy. The safety assessment of this subgroup 1c will be done 7 days after the first treatment. If there will be no major safety concern per-protocol among participants of group 1c, the subgroup 1d participants will be enrolled in the study and given Malaria herbal remedy. The decision to proceed from G1 to the enrolment of G 2 participants will be determined by pre-specified "go or no go" criteria.

Study group 2 will comprise two subgroups of male Adults aged 18 to 45 years with uncomplicated malaria. The first is study group 2a of 52 uncomplicated malaria patients who will be treated with the malaria herbal remedy (Maytenus senegalensis) while G2b of 52 uncomplicated malaria patients will be treated with Artemether-lumefantrine. Patients will be followed up for 56 days. In the presence of failure for either the herbal remedy and Artemether-lumefantrine and Early Treatment Failure criteria met, the rescue treatment will be used.

The purpose of utilizing Group 1 participants is to assess the safety and tolerability of Maytenus senegalensis and proof of the concept that the herbal product is safe for the human subject. Therefore, the decision to proceed to Group 2 intervention for patients with naturally acquired malaria will be subjected to pre-specified "go or no go" criteria. These criteria will be based on safety data obtained from the sentinel group of 12 participants on day 28 after the first treatment and will be reviewed by an independent safety monitoring committee (SMC) appointed for this study. If one of the following criteria will be met, the study will not enroll the remaining G2 participants: (i)Any SAE related to the antimalarial herbal remedy (ii) ≥50% of the participants experienced a Grade 3 AR persisting at Grade 3 for > 48 hours during the 14 follow-up days.

03

Conditions studied

  • Malaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Group 1

Inclusion Criteria:

  • Healthy males based on clinical and laboratory findings
  • Aged from 18 to 45 years
  • Adults with a (BMI) 18 to 30 Kg/m2.
  • Long-term (at least one year) or permanent residence in the Bagamoyo district or nearby districts.
  • Agreement to release medical information and to inform the study doctor concerning for participation in the study.
  • Willingness to be attended to by a study clinician and take all necessary medications prescribed during the study period
  • Agreement to provide contact information of a third-party household member or close friend to study team
  • Availability through mobile phone 24 hours during the entire study period
  • Agreement not to participate in another clinical trial during the study period
  • Agreement not to donate blood during the study period
  • Able and willing to complete the study visit schedule over the study follow up period, including the hospitalizations required for protocol compliance
  • Willingness to undergo , (HBV) and (HCV) tests
  • Able to demonstrate their understanding of the study by responding correctly to 10 out of 10 true/false statements (in a maximum of two attempts for those who failed to respond correctly to all true/false statements in the first attempt)
  • Signed written , in accordance with local practice
  • Free from malaria parasitaemia by blood smear at enrolment

Exclusion Criteria:

  • Previous receipt of an malaria drug in the last 5 years
  • Participation in any other clinical study involving investigational medicinal products within 30 days prior to the onset of the study or during the study period
  • History of arrhythmias or prolonged -interval or another cardiac disease, or abnormalities in (ECG) at screening
  • Positive family history in a 1st or 2nd-degree relative for the cardiac disease at age \<50 years old
  • A history of psychiatric disease
  • Suffering from any chronic illness including; diabetes mellitus, cancer or HIV/AIDS
  • Any confirmed or suspected or immune-deficient condition, including asplenia
  • History of drug or alcohol abuse interfering with normal social function
  • The use of chronic immunosuppressive drugs or other immune-modifying drugs within three months of study onset except inhaled and topical .
  • Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis
  • Positive HIV, hepatitis B virus or hepatitis C virus tests
  • Suspected of having clinically active TB by history or physical examination with positive QuantiFERON-TB Gold Test In-Tube assay
  • Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, blood, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers.
  • Any medical, social condition, or occupational reason that, in the judgment of the study clinician, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent, increases the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data

Group 2

Inclusion Criteria:

  • Male adults aged from 18 to 45 years
  • Ability to swallow oral medication
  • Adults with a Body Mass Index (BMI) 18 to 30 Kg/m2.
  • Uncomplicated malaria, with microscopically confirmed mono-infection by P. falciparum (parasitaemia ≥1.000/ μL and \<200,000/ μL).
  • History of fever anytime during the preceding 24 hours or presence of fever (axillary temperature ≥37.5 °C or rectal ≥38.0 °C).
  • Ability to understand the nature of the trial
  • Ability and willingness to comply with the protocol for the duration of the study, study visit schedule and to provide informed consent from.
  • Stable residence in the study area during the two months after recruitment.

Exclusion Criteria:

  • A history of antimalarial drug use such as Amodiaquine, Chloroquine, Quinine or lumefantrine-based compounds within the previous 6 weeks, with Piperaquine-based compound, or Mefloquine, or Sulphadoxine/pyrimethamine (SP) within the previous 3 months and with Halofantrine within the 30 days prior to screening.
  • Any other antimalarial drug or antibiotics use with antimalarial activity (including cotrimoxazole) and any herbal products, within the 7 days prior to screening.
  • Presence of any febrile condition due to severe diseases other than malaria (e.g. measles, pneumonia, typhoid fever, UTI, meningitis
  • Presence of general danger signs or signs of severe falciparum malaria according to the definitions of WHO
  • Known to the artemisinin-based therapy.
  • History of the relevant clinical allergic reaction of any origin.
  • Known moderate/ severe renal or liver insufficiency.
  • Evidence of clinically relevant hematological, pulmonary, metabolic-endocrine, neurological, urogenital diseases as judged by the study clinician.
  • Suffering from any chronic illness including; cancer or HIV/AIDS or hepatitis B virus (HBV) or HCV infection
  • Previous admission for, or evidence of symptomatic cardiac arrhythmias or with clinically relevant bradycardia at screening (bpm \< 40).
  • Family history of sudden death, or known congenital prolongation of the QT interval, or any clinical condition known to prolong the QT interval.
  • Any other ECG abnormality that requires urgent management.
  • Gastrointestinal dysfunction that could alter absorption or motility (i.e. malabsorption syndromes, intestinal sub occlusion or previous major gastrointestinal surgery).
  • Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis
  • Severe anemia ( \< 7.9 g/dL).
  • Participation in any investigational drug study during the 42 days prior to screening
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Group 1

    • Experimental: Group 1a: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 400mg once a day to test its safety and tolerability. Interventions: o Drugs: Maytenus senegalensis • Experimental: Group 1b: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 600mg once a day to test its safety and tolerability. Interventions: o Drugs: Maytenus senegalensis • Experimental: Group 1c: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability. Interventions: o Drugs: Maytenus senegalensis • Experimental: Group 1d: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability. Interventions: o Drugs: Maytenus senegalensis

    Drug: Maytenus Senegalensis

  • Experimental
    Group 2a

    Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Maytenus senegalensis. Patients will be treated with Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days. Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection Interventions: o Drugs: Maytenus senegalensis

    Drug: Maytenus Senegalensis

  • Active comparator
    Group 2b

    Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Artemether-lumefantrine Patients will be treated with Artemether 20mg/lumefantrine 120mg administered orally by a six-dose regimen over 3 days. Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection Interventions: o Drugs: Artemether 20mg/lumefantrine 120mg

    Drug: Maytenus Senegalensis

Interventions

  • DrugMaytenus Senegalensis

    * Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days. * Artemether 20mg/lumefantrine 120mg

    Also known as: Artemether-lumefantrine

06

What researchers measure

Primary outcomes

  1. Number of participants with clinical significance abnormal values in hematology parameters during the follow up period of 28 days for all participants of group 1 and 2.

    Blood samples will be collected for the analysis of hematology parameters including Red cell blood count (RBC), hemoglobin (HBG), platelets (PLT), white blood cell count (WBC) with differential (neutrophil (NEUT), lymphocyte (LYMPH), and eosinophil (EO)) counts. Blood sample will be collected at Day 0(Baseline), Day 3, day 7, Day 14 and Day 28 Clinical significance abnormal values hematology parameter will be determined by adapted FDA Toxicity Grading Scale.

    Time frame: up period of 28 days

  2. Number of participants with clinical significance abnormal values in biochemistry parameters during the follow up period of 28 days for all participants of group 1 and 2.

    Blood samples will be collected for the analysis of biochemistry parameters including ASAT, bilirubin total and creatinine. Blood sample will be collected at Day 0(Baseline), Day 3, day 7, Day 14 and Day 28. Clinical significance abnormal values of Biochemistry parameters will be determined by adapted FDA Toxicity Grading Scale.

    Time frame: up period of 28

  3. Number of participants with significant changes in vital signs comparing to baseline during the follow up period of 28 days for all participants of group 1 and 2.

    Vital signs assessment included heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Assessments were completed at Day 0 (Baseline), Day 1 up to Day 7, Day 14, and Day 28. We be reviewed using locally prepared normal range for vital sign

    Time frame: up period of 28

  4. Number of AEs during the follow up period of 28 days for all participants of group 1 and 2

    An Adverse Event is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The analysis was performed on all participants who received at least one dose of study treatment.

    Time frame: up period of 28

  5. Number of SAEs during the follow up period of 56 days for all participants of group 1 and 2

    SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/ incapacity, other situations and is associated with liver injury or impaired liver function. The analysis was performed on all participants who received at least one dose of study treatment.

    Time frame: Up period of 56

  6. Number of participants of group 2 with Early Treatment Failure (ETF),

    Development of danger signs or severe malaria on Day 1, Day 2 or Day 3 in the presence of parasitaemia, parasitaemia on Day 2 higher than on Day 0, irrespective of axillary temperature, parasitaemia on Day 3 with axillary temperature ≥ 37.5 ºC and parasitaemia on Day 3 ≥ 25% of count on day 0.

    Time frame: Day 1 up to 3

  7. Number of participants of group 2 with Late Treatment Failure (LTF)

    Development of danger signs or severe malaria on any day from day 4 to day 28 in the presence of parasitaemia; without previously meeting any of the criteria of Early Treatment Failure; Presence of parasitemia + axillary temperature ≥37.5°C on any day from Day 4 to Day 28, without previously meeting any criteria of ETF.

    Time frame: Day 4 up to 28

  8. Number of participants of group 2 with Late parasitology failure (LPF)

    Presence of parasitemia on any day from D7 to D28 + axillary temperature \<37.5°C, without previously meeting any of the criteria of ETF

    Time frame: Day 7-28

Secondary outcomes

  1. Number of participants of group 2 with Adequate Clinical and Parasitological Response (ACPR)

    Absence of parasitaemia on day 28 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure.

    Time frame: 28 days

Other outcomes

  1. Number of developed early ring stage P. falciparum parasites

    A blood sample for in vitro drug testing will be collected from the participants of study group 2b on days 0, 3, 14 and 28 in order to evaluate in vitro susceptibility of P. falciparum isolates to Artemether-lumefantrine (Determination of early ring stage of P. falciparum)

    Time frame: Day 0,3,14 and 28

  2. Percentage of inhibitory concentration (IC50 and IC90) values of the Artemether-lumefantrine

    A blood sample for in vitro drug testing will be collected from the participants of study group 2b on days 0, 3, 14 and 28 in order to evaluate in vitro susceptibility of P. falciparum isolates to Artemether-lumefantrine

    Time frame: Day 0,3,14 and 28

  3. Percentage of identified resistance molecular marker of Artemether-lumefantrine

    Two to three drops of blood will be collected on filter paper from the participants of study Group 2b on days 0, 3, 7, 14, 28 and 56 to study the polymorphism or copy number of pfcrt, pfmdr1, pfdhfr and pfdhps genes, which are considered as markers of resistance to Artemether-lumefantrine

    Time frame: Day 0,3,7,14,28 and 56

07

Study locations

1 site
  • Bagamoyo Clinical Trial Facility
    Bagamoyo, Tanzania
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2022, 15 months.

Of 39 phase 2 interventional studies under Malaria, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's 15 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2021
First posted
Jun 30, 2021
StartActual
Jun 2, 2021
Primary completionActual
Sep 25, 2022
CompletionActual
Sep 25, 2022
Last update
Jul 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04944966
Lead sponsor
Ifakara Health Institute
Collaborators
Swiss Tropical & Public Health Institute, Muhimbili University of Health and Allied Sciences, National Institute for Medical Research, Tanzania
Responsible party
Sponsor
First posted
Jun 30, 2021
Start date
Jun 2, 2021
Primary completion
Sep 25, 2022
Completion
Sep 25, 2022
Last update
Jul 18, 2023

Study contacts

Kamaka Kassim, BscN,MPH
principal investigator · Ifakara Health Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion